|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | | **Please read the checklist for submitting comments at the end of this form.** We cannot accept forms that are not filled in correctly.  We would like to hear your views on the draft recommendations presented in the guideline, and any comments you may have on the rationale and impact sections in the guideline and the evidence presented in the evidence reviews documents. We would also welcome views on the Equality Impact Assessment.  In addition to your comments below on our guideline documents, we would like to hear your views on these questions:   1. Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why. 2. Would implementation of any of the draft recommendations have significant cost implications? 3. What would help users overcome any challenges? (For example, existing practical resources or national initiatives, or examples of good practice.) 4. As part of the update to this guideline, we have removed recommendations regarding the use of glycoprotein inhibitors as part of the early management for people with unstable angina or NSTEMI. It was felt that they would be unlikely to be used in practice with the antiplatelet therapies that are now recommended (parusgrel or ticagrelor) owing to the potential for increased bleeding. Do you agree with this approach? 5. NICE acknowledges that care may be affected by the current COVID-19 situation, however most of the content of the guideline was developed before this arose. Please tell us if there are any particular issues we should take account of in finalising the guideline for publication.   See [[Developing NICE guidance: how to get involved](http://www.nice.org.uk/process/pmg22/chapter/how-you-can-get-involved)](https://www.nice.org.uk/process/pmg20/resources/developing-nice-guidelines-how-to-get-involved-2722986687/chapter/commenting-on-a-draft-guideline) for suggestions of general points to think about when commenting. | | |
| Organisation name – Stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank): | | [**Insert organisation name**] | | |
| Disclosure  Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry. | | [**Insert disclosure here**] | | |
| Name of commentator person completing form: | | [**Insert your name here**] | | |
| Type | | [office use only] | | |
| **Comment number** | **Document**  **[guideline, evidence review A, B, C etc., methods or other (please specify which)]** | Page number  Or **‘general’** for comments on whole document | Line number  Or **‘general’** for comments on whole document | Comments Insert each comment in a new row.  Do not paste other tables into this table, because your comments could get lost – type directly into this table. |
| Example 1  Example 2  Example 3  Example 4  Example 5  Example 6  Example 7 | Guideline  Guideline  Guideline  Guideline  Evidence review C  Methods  Algorithm | 16  17  23  37  57  34  General | 45  23  5  16  32  10  General | We are concerned that this recommendation may imply that …………..  Question 1: This recommendation will be a challenging change in practice because ……  Question 3: Our trust has had experience of implementing this approach and would be willing to submit its experiences to the NICE shared learning database. Contact……………….  This rationale states that…  There is evidence that …  The inclusion criteria …  The algorithm seems to imply that … |
| 1 |  |  |  |  |
| 2 |  |  |  |  |
| 3 |  |  |  |  |
| 4 |  |  |  |  |
| 5 |  |  |  |  |
| 6 |  |  |  |  |

Insert extra rows as needed

|  |
| --- |
| **Checklist for submitting comments**   * Use this comment form and submit it as a **Word document (not a PDF)**. * Complete the disclosure about links with, or funding from, the tobacco industry. * Include **page and line number (not section number)** of the text each comment is about. * Combine all comments from your organisation into 1 response. **We cannot accept more than 1 response from each organisation**. * Do not paste other tables into this table – type directly into the table. * Ensure each comment stands alone; do not cross-refer within one comment to another comment. * **Clearly mark any confidential information or other material that you do not wish to be made public. Also, ensure you state in your email to NICE that your submission includes confidential comments.** * **Do not name or identify any person or include medical information about yourself or another person** from which you or the person could be identified as all such data will be deleted or redacted. * Spell out any abbreviations you use * For copyright reasons, **do not include attachments** such as research articles, letters or leaflets. We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline. * **We do not accept comments submitted after the deadline stated for close of consultation.**   You can see any guidance that we have produced on topics related to this guideline by checking [NICE Pathways](http://pathways.nice.org.uk/).  **Note:** We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.  Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.  **Data protection**  The information you submit on this form will be retained and used by NICE and its advisers for the purpose of developing its guidance and may be passed to other approved third parties.Please do not name or identify any individual patient or refer to their medical condition in your comments as all such data will be deleted or redacted. The information may appear on the NICE website in due course in which case all personal data will be removed in accordance with NICE policies.  By submitting your data via this form you are confirming that you have read and understood this statement.  For more information about how we process your data, please see our [privacy notice](https://www.nice.org.uk/privacy-notice). |